Si è verificato un errore durante il caricamento della pagina.
Il nostro team è stato avvisato ma contattaci tramite il Widget assistenza email se il problema persiste.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | 361,3x - 399,4x | 380,4x |
| Selected Fwd EBIT Multiple | 41,1x - 45,4x | 43,2x |
| Fair Value | ₩211.953 - ₩234.095 | ₩223.024 |
| Upside | -40,5% - -34,2% | -37,4% |
| Benchmarks | Ticker | Full Ticker |
| SK bioscience Co.,Ltd. | A302440 | KOSE:A302440 |
| SK Biopharmaceuticals Co., Ltd. | A326030 | KOSE:A326030 |
| Hugel, Inc. | A145020 | KOSDAQ:A145020 |
| Genome & Company | A314130 | KOSDAQ:A314130 |
| Genexine, Inc. | A095700 | KOSDAQ:A095700 |
| ALTEOGEN Inc. | A196170 | KOSDAQ:A196170 |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| A302440 | A326030 | A145020 | A314130 | A095700 | A196170 | ||
| KOSE:A302440 | KOSE:A326030 | KOSDAQ:A145020 | KOSDAQ:A314130 | KOSDAQ:A095700 | KOSDAQ:A196170 | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | NM- | NM- | 19.5% | NM- | NM- | NM- | |
| 3Y CAGR | NM- | 0.5% | 20.2% | NM- | NM- | NM- | |
| Latest Twelve Months | -1054.8% | 356.8% | 41.2% | 56.1% | -2.0% | 360.9% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | -2.3% | -477.5% | 37.9% | -3537.1% | -356.6% | -26.1% | |
| Prior Fiscal Year | -3.2% | -10.6% | 36.8% | -385.4% | -208.7% | -10.1% | |
| Latest Fiscal Year | -51.7% | 17.6% | 44.6% | -87.2% | -947.2% | 24.7% | |
| Latest Twelve Months | -51.7% | 17.6% | 44.6% | -87.2% | -743.5% | 24.7% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 9.81x | 14.04x | 8.96x | 2.64x | 4.90x | 181.84x | |
| EV / LTM EBITDA | -29.4x | 67.6x | 18.4x | -4.4x | -0.7x | 662.0x | |
| EV / LTM EBIT | -19.0x | 79.8x | 20.1x | -3.0x | -0.7x | 736.2x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -19.0x | -0.7x | 79.8x | ||||
| Historical EV / LTM EBIT | -1259.4x | -96.3x | 736.2x | ||||
| Selected EV / LTM EBIT | 361.3x | 380.4x | 399.4x | ||||
| (x) LTM EBIT | 25,404 | 25,404 | 25,404 | ||||
| (=) Implied Enterprise Value | 9,179,298 | 9,662,419 | 10,145,540 | ||||
| (-) Non-shareholder Claims * | 85,855 | 85,855 | 85,855 | ||||
| (=) Equity Value | 9,265,153 | 9,748,274 | 10,231,395 | ||||
| (/) Shares Outstanding | 53.3 | 53.3 | 53.3 | ||||
| Implied Value Range | 173,846.18 | 182,911.19 | 191,976.20 | ||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 173,846.18 | 182,911.19 | 191,976.20 | 356,000.00 | |||
| Upside / (Downside) | -51.2% | -48.6% | -46.1% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | A302440 | A326030 | A145020 | A314130 | A095700 | A196170 | |
| Enterprise Value | 2,503,449 | 7,572,771 | 3,317,365 | 71,273 | 23,479 | 18,887,208 | |
| (+) Cash & Short Term Investments | 1,158,108 | 324,489 | 423,119 | 80,930 | 52,501 | 185,253 | |
| (+) Investments & Other | 22,357 | 91,439 | 23,433 | 0 | 173,922 | 2,654 | |
| (-) Debt | (392,814) | (184,482) | (37,606) | (32,024) | (68,665) | (11,759) | |
| (-) Other Liabilities | (219,887) | (27,711) | (37,029) | (50,753) | 0 | (498) | |
| (-) Preferred Stock | 0 | 0 | 0 | (883) | 0 | (89,796) | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 3,071,214 | 7,776,506 | 3,689,282 | 68,544 | 181,237 | 18,973,063 | |
| (/) Shares Outstanding | 78.3 | 78.3 | 11.0 | 31.1 | 45.5 | 53.3 | |
| Implied Stock Price | 39,200.00 | 99,300.00 | 335,000.00 | 2,205.00 | 3,985.00 | 356,000.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 39,200.00 | 99,300.00 | 335,000.00 | 2,205.00 | 3,985.00 | 356,000.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |